Cephalon (CEPH) Inactive 10-K2006 FY Annual report

Filed: 28 Feb 07, 12:00am

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. freshman Good

New words: abide, abstain, accessible, AMBIT, amplify, anemia, apnea, Apotex, asthenia, Bioscience, blended, brought, cap, carbon, chargeable, child, circulatory, CLL, column, complaint, constipation, consumption, contact, context, curtain, decade, declaratory, dehydration, dioxide, disgorgement, DoD, drinking, DURSOLV, duty, Eastern, edema, Edinburgh, entrant, equitable, eroded, erosion, etiology, evenly, False, FENTORA, fiduciary, filer, FONLIPOL, forfeiture, formulary, foundation, franchise, genome, grew, HIV, hypotension, improperly, Infirmary, input, insignificant, Inspector, instance, interrogating, invoked, iron, isolated, kinome, Lesley, logistical, mantle, MedImmune, memo, merit, messenger, midpoint, mild, molar, monetary, MRCP, multiemployer, multifunctional, myeloproliferative, NCI, neurodegeneration, newly, nonvested, OLMIFON, OTFC, outpatient, overactive, overfunded, petition, ph, pharmacotherapy, plaintiff, polymorph, polymorphic, pool, postponement, profound, propriety, prosecutorial, psychological, Psychopharmacologic, purported, purportedly, rash, ratification, rear, reconcile, regression, remission, retrospective, retrospectively, Road, rollover, ruling, Russell, SAB, saleable, saliva, SAP, schizophrenia, Scotland, shock, Sick, SJS, skin, Takeda, threshold, tooth, Traditionally, transient, transitory, Tricare, turnover, underfunded, undergo, understood, unenforceable, unfunded, unique, unrecognized, unspecified, upper, VESANOID, VIGIL, voluntarily, Watson, windfall

Removed: activation, biochemical, Blake, buflomedil, Cardiology, comfort, communicate, depletion, diminish, distinct, distributed, dominated, dysfunction, emanating, endpoint, enrolling, entitled, explore, extremely, flexibility, gabapentin, house, ideal, identifiable, improved, inhibiting, inhibitory, initiated, irritability, lifespan, London, neurology, neuronal, NEURONTIN, page, painful, Pfizer, precipitated, prevented, Proliance, representative, represented, seizure, stream, substantiated, tailored, training, transmitter, unamortized

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

Related press release

CEPH similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

Exhibit 12.1

Cephalon, Inc

Computation of Ratio of Earnings to Fixed Charges

(Amounts in thousands)

	2002		2003		2004			2005			2006
Determination of Earnings:
Pre-tax income (loss) from continuing operations	$	62,433	$	130,314	$	(28,184	)	$	(245,118	)	$	238,254
Add:
Amortization of interest capitalized in current or prior periods	—		—		—			—			52
Fixed charges	39,648		31,191		25,623			30,985			28,171
Total Earnings	$	102,081	$	161,505	$	(2,561	)	$	(214,133	)	$	266,477


Fixed charges:
Interest expense and amortization of debt discount and premium on all indebtedness	38,215		28,905		22,186			25,235			18,922
Appropriate portion of rentals	1,433		2,286		3,437			5,750			9,249
Preferred stock dividend requirements of consolidated subsidiaries	—		—		—			—			—
Fixed charges	39,648		31,191		25,623			30,985			28,171

Capitalized interest	—		—		—			1,044			1,766

Total Fixed Charges	$	39,648	$	31,191	$	25,623		$	32,029		$	29,937

Ratio of earnings to fixed charges (1)	2.57		5.18		—			—			8.90

Deficiency of earnings to fixed charges	—		—		28,184			246,162			—

(1) For the years ended December 31, 2004 and 2005 no ratios are provided because earnings were insufficient to cover fixed charges and fixed charges and preferred dividends, respectively.